Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
Phase 1
30
about 9.1 years
18+
Male only
1 site in FL
What this study is about
This trial is testing a treatment with genetically modified T cells for men with advanced, castration-resistant prostate cancer. The goal of this phase 1 clinical trial is to determine the safety and effectiveness of this new approach.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive MSGV1-PSCA-8T28Z
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine
infusion
Primary: Maximum Tolerated Dose (MTD) of MSGV1-PSCA-8T28Z
Secondary: Best Prostate Specific Antigen (PSA) Response rate, Radiographic progression-free survival (rPFS)
Oncology